
Please try another search
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Name | Age | Since | Title |
---|---|---|---|
Carolyn Majcher | - | - | Member of Advisory Board |
Jim Mccollum | - | - | - |
Evert B. Schimmelpennink | 53 | 2021 | President, CEO, Secretary & Director |
John Doane | - | - | Member of Medical Advisory Board |
Jeffrey P. George | 51 | 2024 | Independent Chairman |
Shelley B. Thunen | 71 | 2024 | Independent Director |
James W. McCollum | 69 | 2024 | Co-Founder & Director |
Steven J. Dell | - | - | Member of Medical Advisory Board |
Colman Kraff | - | - | Member of Medical Advisory Board |
Frederic Guerard | 52 | 2024 | Independent Director |
Zachary Scheiner | 48 | 2020 | Independent Director |
Robert H. Osher | - | - | Member of Medical Advisory Board |
Kimberlee Cobleigh Drapkin | 57 | 2023 | Independent Director |
Michael Kling | - | - | Member of Advisory Board |
Kathryn Hatch | - | - | Member of Medical Advisory Board |
Deepinder Dhaliwal | - | - | Member of Medical Advisory Board |
Andrew Morgenstern | - | - | Member of Advisory Board |
S. Barry Eiden | - | - | Member of Advisory Board |
Louise Sclafani | - | - | Member of Advisory Board |
Stephanie Woo | - | - | Member of Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review